KAI-9531

DRUG6 trials

Sponsors

Kailera Therapeutics Inc., Kailera

Conditions

Healthy VolunteersObesityOverweight

Phase 1

A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices

CompletedNCT07044401

KaileraHealthy Volunteers

Start: 2025-07-14End: 2025-11-13Updated: 2025-12-05

Phase 3

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

RecruitingNCT07284875

KaileraObesity, Overweight

Start: 2025-12-18End: 2028-03-27Target: 1800Updated: 2026-06-18

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

RecruitingNCT07284979

Start: 2025-12-30End: 2028-04-17Target: 1200Updated: 2026-06-18

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes

Not yet recruitingCTIS2025-523511-11-00

Kailera Therapeutics Inc.Obesity

Target: 126Updated: 2026-04-29

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes

Not yet recruitingCTIS2025-523510-87-00

Kailera Therapeutics Inc.Obesity

Target: 37Updated: 2026-05-04

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes

Not yet recruitingCTIS2025-523486-17-00

Kailera Therapeutics Inc.Obesity

Target: 79Updated: 2026-05-05